The modulation of gene expression in osteoblasts by thrombin coated on biphasic calcium phosphate ceramic.
For many years, fibrin sealants were associated with bone substitutes to promote bone healing. However, the osteoblastic response to fibrin sealant components remains poorly documented. In this study, MC3T3-E1 osteoblastic cells were cultured on biphasic calcium phosphate ceramic (MBCP) coated with Tissucol components (thrombin and fibrinogen). Analysis of osteoblastic differentiation markers by RT-PCR revealed that MBCP coated with Tissucol stimulated mRNA levels for osteocalcin and alkaline phosphatase (ALP). Of all the components of Tissucol, thrombin has been reported to affect osteoblastic behavior. Our results demonstrated that low thrombin concentrations (0.5-5 U/ml) stimulated mRNA levels for ALP, whereas high thrombin concentrations (50-100 U/ml) decreased mRNA levels for ALP and PTH/PTHrP receptor and also increased mRNA level for the osteoclastogenesis inhibitor OPG. As thrombin stimulated angiogenesis, we then wondered whether thrombin could influence the expression of angiogenic factors. Low thrombin concentrations were shown to up-regulate mRNA levels for VEGF-B and VEGF-R1, suggesting an autocrine/paracrine role for VEGF-B. Higher thrombin concentrations also up-regulated mRNA for VEGF-A and neuropilin-1. In conclusion, the association of MBCP with thrombin and fibrinogen appears to be a convenient scaffold for bone cell differentiation. Thrombin could also acts at the cellular level by increasing the angiogenic potential of osteoblasts as well as their responsiveness to thrombin and VEGF.
Bluteau
Gilles
G
INSERM UMRS 791, Laboratory of Osteoarticular and Dental Tissue Engineering, University of Nantes, School of Dental Surgery, 1 Place Alexis Ricordeau, 44042 Nantes cedex 1, France.
Pilet
Paul
P
Bourges
Xavier
X
Bilban
Melitta
M
Spaethe
Reiner
R
Daculsi
Guy
G
Guicheux
Jérôme
J
D000818:Animals; D018786:Bone Substitutes / Q000008:administration & dosage / Q000494:pharmacology; D002130:Calcium Phosphates / Q000737:chemistry*; D002454:Cell Differentiation / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D048429:Cell Size / Q000187:drug effects; D002516:Ceramics / Q000737:chemistry; D020099:Coated Materials, Biocompatible / Q000008:administration & dosage; D015718:Fibrin Tissue Adhesive / Q000008:administration & dosage* / Q000737:chemistry; D005786:Gene Expression Regulation / Q000187:drug effects / Q000502:physiology; D051379:Mice; D041681:NIH 3T3 Cells; D010006:Osteoblasts / Q000166:cytology* / Q000187:drug effects / Q000502:physiology*; D018179:Receptors, Thrombin / Q000378:metabolism*; D013917:Thrombin / Q000008:administration & dosage* / Q000737:chemistry; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism*
D018786:Bone Substitutes; D002130:Calcium Phosphates; D020099:Coated Materials, Biocompatible; D015718:Fibrin Tissue Adhesive; D018179:Receptors, Thrombin; D042461:Vascular Endothelial Growth Factor A; D013917:Thrombin; C485829:calcium phosphate, dibasic, anhydrous